tbuckley/cabot-search huggingface dataset:
PD2-2-3: Prognostic significance of L1 cell adhesion molecule (CAM) expression in pulmonary neuroendocrine tumors
Authors: Hyo Song Kim, Keunchil Park, Hyun Jung Jun, Seong Yoon Yi, Joungho Han, Jin Seok Ahn, Myung-Ju Ahn, Won Ki Kang, Jinman Kim, Hyo-Jeong Hong
Journal: Journal of Thoracic Oncology (2007)
Associations between Recreational and Commuter Cycling, Changes in Cycling, and Type 2 Diabetes Risk: A Cohort Study of Danish Men and Women
Authors: Martin G. Rasmussen, Anders Grøntved, Kim Blond, Kim Overvad, Anne Tjønneland, Majken K. Jensen, Lars Østergaard
Journal: PLoS Medicine (2016)

Background Cycling is a recreational activity and mode of commuting with substantial potential to improve public health in many countries around the world. The aim of this study was to examine prospective associations between recreational and commuter cycling, changes in cycling habits, and risk of type 2 diabetes (T2D) in Danish adults from the Diet, Cancer and Health cohort study. Methods and Findings At baseline from 1993 to 1997, 24,623 men and 27,890 women from Denmark, 50–65 y of age and free of T2D and other chronic diseases, underwent a number of assessments, including completing a lifestyle questionnaire also addressing cycling habits. Approximately 5 y later, at a second examination, participants completed a new, updated lifestyle questionnaire. Cox regression was used to estimate hazard ratios (HRs) of incident T2D registered in the Danish National Diabetes Registry, according to recreational and commuter cycling and changes in cycling habits, with adjustment for a priori known T2D risk factors. During 743,245.4 person-years of follow-up (mean follow-up 14.2 y), 6,779 incident cases of T2D were documented. Multivariable adjusted HRs (95% confidence interval [CI]) were 1, 0.87 (0.82, 0.93), 0.83 (0.77, 0.89), 0.80 (0.74, 0.86) and 0.80 (0.74, 0.87) (p for trend = <0.001) for 0, 1–60, 61–150, 151–300, and >300 min/wk of total cycling (recreational and commuter cycling), respectively. In analysis of seasonal cycling, multivariable adjusted HRs (95% CI) were 1, 0.88 (0.83, 0.94), and 0.80 (0.76, 0.85) for non-cyclists, seasonal cyclists (those cycling only in summer or winter), and those cycling during both summer and winter, respectively. How changes in total cycling from baseline to the second examination affected risk was also investigated, and multivariable adjusted HRs (95% CI) were 1, 0.88 (0.78, 1.01), 0.80 (0.69, 0.91), and 0.71 (0.65, 0.77) for non-cyclists and for those who ceased, initiated, or continued cycling between baseline and the second examination, respectively. Lastly, in the analysis of commuter cycling, multivariable HRs (95% CI) were 1, 0.72 (0.60, 0.87), 0.83 (0.69, 1.00), and 0.70 (0.57, 0.85) (p for trend = <0.001) for cycling 0, 1–60, 61–150, and >150 min/wk to work, respectively. The main limitation of the current study is the use of self-reported physical activity. Conclusions Commuter and recreational cycling was consistently associated with lower risk of T2D in Danish adults. Our results also provide evidence that late-in-life initiation of or continued engagement in cycling lowers risk of T2D.
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
Journal: New England Journal of Medicine (2003)

Previous trials evaluating aspirin and other nonsteroidal antiinflammatory drugs for preventing colorectal adenomas have used populations at average risk. This randomized, double-blind, placebo-controlled study, the Colorectal Adenoma Prevention Study, evaluated 325 mg per day of aspirin in patients 30 to 80 years of age who had histologically confirmed colon or rectal cancer but were at low risk of recurrence after curative resection of the primary tumor. Those with more advanced disease were eligible if they had been disease-free for longer than 5 years after resection. Colonoscopy was done as part of the usual follow-up routine. A total of 517 patients, 258 randomized to receive placebo and 259 to aspirin, had at least one colonoscopy after randomization; the median interval to the first examination was 11 months. Fewer aspirin-treated patients developed adenomas; 17% of them had at least one adenoma, compared with 27% for placebo patients. The relative risk of a new adenoma in the aspirin group was 0.65 after adjusting for age, sex, stage of cancer, number of colonoscopies, and time to a first postrandomization colonoscopy. The hazard ratio for a new polyp was 0.64 in the aspirin group. Adenomas were of comparable size in the 2 groups, as were the numbers of patients whose adenomas were at least 1 cm in diameter. No substantial difference in adverse effects was noted. A daily 325-mg dose of aspirin lowers the risk of adenoma in patients followed up after resection of a primary colorectal cancer. Despite this clear protective effect, adenomas did develop in some aspirin-treated patients. Aspirin cannot be recommended as a replacement for surveillance colonoscopy.
Discrimination and quality of life among breast cancer survivors.
Authors: Scarlett Lin Gomez, Felisa A Gonzales, Salma Shariff-Marco, Laura A Dwyer, Amani Nuru-Jeter
Journal: Journal of Clinical Oncology (2016)

250 Background: We examined the role of race/ethnicity, education, and medical discrimination on global and breast cancer-specific (BCS) quality of life (QoL). Methods: Telephone interviews were administered to 536 Asian, Black, Hispanic and White women identified through the Greater Bay Area Cancer Registry who were aged 20+ when diagnosed with a first invasive primary breast cancer between 2006 and 2009. Women reported perceptions of discriminatory experiences while receiving breast cancer care. QoL was assessed with a single item asking about global QoL over the past 4 weeks ( “excellent” vs “less than excellent”) and a summary score for the 6-item breast cancer subscale of the FACT-B (higher scores indicated more concerns (or worse QoL)). Race/ethnicity and education were combined into an 8-category variable (4 race/ethnic groups x 2 education groups). Psychometric analyses was used to create a summed medical discrimination score using 7 items that comprised a single factor, and split into tertiles to indicate no, low, and moderate/high levels of discrimination. Main effects for race/ethnicity x education and medical discrimination were identified using logistic and linear regression models. Adjusted analyses controlled for age, marital status, health insurance, stage, histology, and tumor size. Results: In adjusted analyses, disparities across combined race/ethnicity x education groups were observed for global QoL (Wald χ 2 (7) = 23.32, p &lt; 0.01) but not for BCS QoL (F= 0.78, p= 0.60). Black and Asian women reported lower global QoL than college-educated White women. Medical discrimination was related to global (Wald χ 2 (2) = 6.98, p= 0.03) and BCS QoL (F= 6.14, p&lt; 0.01). Women reporting moderate/high levels of medical discrimination had significantly lower odds of excellent QoL (OR= 0.416, p&lt; 0.01) and more breast cancer concerns (β= 1.19, t= 3.50, p&lt; 0.001) than women reporting no discrimination. Conclusions: Medical discrimination was associated with lower global and BCS QoL. More research is needed to identify specific factors at the individual, provider, and organizational levels that contribute to perceptions of medical discrimination so that they can be addressed and QoL can be improved for breast cancer patients.
Confirmatory Testing for Onychomycosis
Authors: Apphia L. Wang, Boni E. Elewski, Craig A. Elmets
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Peptides for nucleic acid delivery
Authors: Taavi Lehto, Kariem Ezzat, Matthew J.A. Wood, Samir EL Andaloussi
Journal: Advanced Drug Delivery Reviews (2016)

Nucleic acids and their synthetic oligonucleotide (ON) analogs are a group of gene therapeutic compounds which hold enormous clinical potential. Despite their undoubted potential, clinical translation of these molecules, however, has been largely held back by their limited bioavailability in the target tissues/cells. To overcome this, many different drug delivery systems have been devised. Among others, short delivery peptides, called cell-penetrating peptides (CPPs), have been demonstrated to allow for efficient delivery of nucleic acids and their ON analogs, in both cell culture and animal models. In this review, we provide brief overview of the latest advances in nucleic acid delivery with CPPs, covering the two main vectorization strategies, covalent conjugation and nanoparticle formation-based approach. In conclusion, CPP-based drug delivery systems have the capacity to overcome the hurdle of delivery and thus have the potential to facilitate the clinical translation of nucleic acid-based therapeutics.
Accumulation of Tc-99m HMDP in Extramedullary Plasmacytoma of the Stomach
Authors: NORIYUKI SHUKE, ATSUTAKA OKIZAKI, WAKAKO YAMAMOTO, KOUKI USUI, TAMIO ABURANO
Journal: Clinical Nuclear Medicine (2001)

SHUKE, NORIYUKI M.D.; OKIZAKI, ATSUTAKA M.D.; YAMAMOTO, WAKAKO M.D.; USUI, KOUKI M.D.; ABURANO, TAMIO M.D. Author Information
Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.
Authors: Alessandra Cesano, Cheryl L Willman, Kenneth J. Kopecky, Urte Gayko, Santosh Putta, Brent Louie, Matt Westfall, Norman Purvis, David Spellmeyer, Carol Marimpietri, James Hackett, Jing Shi, Elisabeth Paietta, Martin S. Tallman, Larry D Cripe, Susan K. Atwater, Frederick R. Appelbaum, Jerald P. Radich
Journal: Blood (2012)
New Madrid
Authors: M Therese Southgate
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Smoking Cessation Drugs Pose Little Neuropsychiatric Risk
Authors: Anita Slomski
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Confirmed case of Zika virus congenital infection, Spain, March 2016
Authors: Sonia Perez, Ruben Tato, Jorge Julio Cabrera, Alberto Lopez, Olga Robles, Eugenio Paz, Amparo Coira, Maria Paz Sanchez-Seco, Ana Vazquez, Raquel Carballo, Carlos Quintas, Anxela Pousa
Journal: Eurosurveillance (2016)

We describe Zika virus (ZIKV) vertical transmission in an imported case in Spain, in a 17-week pregnant woman. ZIKV IgG, IgM and RNA were detected in serum in week 17. At 19 weeks, ultrasound scan revealed fetal malformations and ZIKV was detected in the amniotic fluid. Pregnancy was terminated at week 21; autopsy of the fetus revealed bilateral hydrocephalus, brain microcalcifications and arthrogryposis multiplex congenita. ZIKV was detected in the umbilical cord and brain tissue.
Case 23-1979
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Bernard Kliman, G. Richard Dickersin
Journal: New England Journal of Medicine (1979)

Presentation of CaseA 6 1/2-year-old girl was admitted to the hospital because of sexual precocity.She was born of an uncomplicated, full-term delivery of the first pregnancy in a mother aged 20 years. Her birth weight was 3.5 kg, and her length 49.5 cm. She was considered small for her age but was otherwise well until six months before admission, when slight prominence of the nipples and breasts was observed. A rapid growth spurt followed, and during the year before entry her height increased from 104.1 to 116.8 cm. Her mother noticed the appearance of fine, long pubic hair . . .
Digital Support for Childbirth in Developing Countries
Authors: Claudia Pagliari
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Prognostic value of ECOG performance status in lung cancer assessed by patients and physicians.
Authors: Jakob Johansen, Mogens Karsboel Boisen, Anders Mellemgaard, Bente Holm
Journal: Journal of Clinical Oncology (2013)

8103 Background: Physician-reported Eastern Cooperative Oncology Group (ECOG) performance status (MD-PS) is a reliable prognostic factor of overall survival (OS) and has a major influence on treatment decisions. MD-PS is also used to quantify cancer patients' general well-being and activities of daily life. The extent and prognostic importance of disagreements between MD-PS and cancer patients' self-reported ECOG PS (Pt-PS) have not been adequately evaluated. Methods: Four hundred and sixty consecutive patients with lung cancer (LC) were referred to the Dept. of Oncology at Herlev University Hospital, Denmark, from February 1 2012 to January 31 2013. Three hundred and forty-seven (75%) of these patients were enrolled in a prospective, longitudinal, LC biomarker study, “LUCAS”. Patients assessed their own Pt-PS in a questionnaire at first visit. Treating physicians scored the MD-PS at first visit. Results: Fifty-four (16%) LUCAS patients had missing PS data (39 no Pt-PS; 14 no MD-PS; 1 neither). LUCAS patients were significantly younger than the total LC population (mean age, 68.1 vs. 71.1; t-test: p &lt; 0.01). The MD-PS and Pt-PS were distributed differently in the LUCAS cohort: PS=0 (121 vs. 76), PS=1 (147 vs. 145), PS=2 (39 vs. 54), PS=3 (25 vs. 30), PS=4 (0 vs. 2) (X 2 test: p &lt; 0.01). In 170 (58%) cases the physician and patient were in concordance. In 24 (8%) cases the MD-PS scored the patient in poorer PS compared to the Pt-PS. In 99 (34%) cases the MD-PS scored the patient in better PS than the Pt-PS. In 11 (4%) cases the physician scored a PS value more than 1 different from the patient; all were towards a better PS. The median OS in the total cohort (460 patients) was 9.7 months. MD-PS and Pt-PS were both effective in predicting OS. For patients with MD-PS = 0, a poorer Pt-PS did not significantly predict worse outcome. However, for patients with MD-PS = 1, there was a trend (HR 1.98, p = 0.08; log rank test) towards worse outcome if Pt-PS was &gt; 1. Conclusions: Oncologists and patients frequently disagree regarding PS. The physicians tend to note a better PS score than the patients. The differences between MD-PS and Pt-PS could influence the prognostic value. It may be beneficial in clinical practice to involve patients in PS assessments.
Reconsolidation or re-association?
Authors: Sue Llewellyn
Journal: Behavioral and Brain Sciences (2015)

The target article argues memory reconsolidation demonstrates how therapeutic change occurs, grounding psychotherapy in brain science. However, consolidation has become an ambiguous term, a disadvantage applying also to its derivative - reconsolidation. The concept of re-association (involving active association between memories during rapid eye movement [REM] dreams followed by indexation and network junction instantiation during non-rapid eye movement [NREM] periods) brings greater specificity and explanatory power to the possible brain correlates of therapeutic change.
Results of the German IPEP study evaluating tolerability, efficacy and acceptance of fulvestrant under routine clinical conditions in advanced breast cancer
Authors: M. Warm, A. Thomas, K. Ziegler, C. Moers, R. Kates, N. Harbeck
Journal: Journal of Clinical Oncology (2008)

1092 Background: Fulvestrant is used in the treatment of postmenopausal women with estrogen receptor-positive, locally advanced or metastatic breast cancer. The questions of the study are whether fulvestrant is safe, effective and tolerable. Methods: 848 patients were enrolled in this fulvestrant in practice evaluation programme (IPEP). Under clinical routine conditions in the participating centers regarding selection of subjects, diagnostic procedures or therapeutic decisions, all relevant data was documented over 9 months of fulvestrant therapy in postmenopausal women with advanced ER+ breast cancer who had relapsed during or after adjuvant anti- estrogen treatment, or with disease progression under palliative anti-estrogen therapy. Results: Data of 597 (70%) of patients was evaluable according to protocol. Median age was 64 years, 52% of patients had a co-morbidity, 78% one or more prior palliative therapies. Safety: 15.6% had one or more adverse events, mainly hot flushes, gastrointestinal, or musculo-sceletal symptoms, 27 patients had a serious adverse event, 20 died during observation. Efficacy: after 3 months only 11.5% of patients had progressed; 6% had a complete remission, 16.5% partial remission, 58 % stable disease as locally assessed by the investigators. After 9 months, 15% of evaluable patients had progressed, 13% were in complete remission, 28% in partial remission und 42% had stable disease, 2% are not available. Tolerability: Tolerability was judged as being good to very good by the majority of both investigators and patients with stable tolerability parameters reported at 3, 6 and 9 months (Patients: very good: 43.5%, good: 48%. Specialists: very good: 48%, good: 46%). Conclusions: Overall, fulvestrant showed very good efficacy with a reported clinical benefit rate of 83% after 9 months, safety and tolerability in this observational study in a patient collective with advanced breast cancer. No significant financial relationships to disclose.
Randomized, Controlled Trial of an Advance Care Planning Video Decision Support Tool for Patients With Advanced Heart Failure
Authors: Areej El-Jawahri, Michael K. Paasche-Orlow, Dan Matlock, Lynne Warner Stevenson, Eldrin F. Lewis, Garrick Stewart, Marc Semigran, Yuchiao Chang, Kimberly Parks, Elizabeth S. Walker-Corkery, Jennifer S. Temel, Hacho Bohossian, Henry Ooi, Eileen Mann, Angelo E. Volandes
Journal: Circulation (2016)

Background: Conversations about goals of care and cardiopulmonary resuscitation (CPR)/intubation for patients with advanced heart failure can be difficult. This study examined the impact of a video decision support tool and patient checklist on advance care planning for patients with heart failure. Methods: This was a multisite, randomized, controlled trial of a video-assisted intervention and advance care planning checklist versus a verbal description in 246 patients ≥64 years of age with heart failure and an estimated likelihood of death of &gt;50% within 2 years. Intervention participants received a verbal description for goals of care (life-prolonging care, limited care, and comfort care) and CPR/intubation plus a 6-minute video depicting the 3 levels of care, CPR/intubation, and an advance care planning checklist. Control subjects received only the verbal description. The primary analysis compared the proportion of patients preferring comfort care between study arms immediately after the intervention. Secondary outcomes were CPR/intubation preferences and knowledge (6-item test; range, 0–6) after intervention. Results: In the intervention group, 27 (22%) chose life-prolonging care, 31 (25%) chose limited care, 63 (51%) selected comfort care, and 2 (2%) were uncertain. In the control group, 50 (41%) chose life-prolonging care, 27 (22%) selected limited care, 37 (30%) chose comfort care, and 8 (7%) were uncertain ( P &lt;0.001). Intervention participants (compared with control subjects) were more likely to forgo CPR (68% versus 35%; P &lt;0.001) and intubation (77% versus 48%; P &lt;0.001) and had higher mean knowledge scores (4.1 versus 3.0; P &lt;0.001). Conclusions: Patients with heart failure who viewed a video were more informed, more likely to select a focus on comfort, and less likely to desire CPR/intubation compared with patients receiving verbal information only. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01589120.